LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 ProQR Therapeutics NV. , a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™.
Annual General Meeting Results On May 17, 2023, ProQR Therapeutics N.V. held its 2023 annual general meeting of shareholders at the offices of Allen & Overy LLP, Apollolaan. | May 17, 2023
31.03.2023 - RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. “I am honored to succeed .
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial ResultsAdditional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022Phase 2/3 Sirius and Celeste clinical trials of ult.